Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 22;19(1):306.
doi: 10.1186/s13023-024-03292-w.

Angelman syndrome in Poland: current diagnosis and therapy status-the caregiver perspective: a questionnaire study

Agata Suleja  1   2 , Katarzyna Milska-Musa  3 , Łukasz Przysło  4 , Marzena Bednarczyk  2   5 , Marcin Kostecki  2 , Dominik Cysewski  2   6 , Paweł Matryba  7 , Anna Rozensztrauch  8   9 , Michał Dwornik  10 , Marcin Opacki  11 , Robert Śmigiel  12   13 , Kacper Łukasiewicz  14   15   16
Affiliations

Angelman syndrome in Poland: current diagnosis and therapy status-the caregiver perspective: a questionnaire study

Agata Suleja et al. Orphanet J Rare Dis. .

Abstract

Background: Angelman syndrome (AS) is a rare neurodevelopmental disease caused by imprinting disorders that impede the production of the ubiquitin E3A ligase protein (UBE3A). AS affects multiple systems, with the main symptoms including epilepsy, psychomotor disorders and speech development disorders. To date, no study has been conducted in the Polish population to verify the condition's diagnosis and treatment process.

Results: Seventy patients with the median age of 60 months were included into the analysis. 80% of patients were diagnosed with deletion, 19.9% with a mutation of UBE3A gene, 4.3% with paternal uniparental disomy (UPD) and 2.8% with an imprinting defect. The mean age of first symptoms was 5 months, while the mean age of diagnosis was 29 months (earliest in deletion group at 23 months), and the median duration of diagnosis process was 7 months. The average time to a clinical geneticist appointment was 3 months. 37.9% of the patients initially received a different diagnosis. Epileptic seizures were present in 88.6% of the individuals. 98.6% of the studied group were under care of a pediatric neurologist, 47.1% of a gastroenterologist. A ketogenic diet was used in 7.1% of patients. Caregivers identified finding a specialist suitable for AS patients and access to genetic testing as the biggest problems.

Conclusions: The care of patients with AS in Poland is carried out according to the European and world standards, however there is an impeded access to clinical geneticist, and the knowledge about rare diseases among primary healthcare physicians could be improved. Moreover, access to AS care specialists and coordination of care is limited. There is a need for creation a specialized centers and databases for AS patients.

Keywords: Angelman syndrome; Genetic testing; Healthcare organisation; Rase diseases.

PubMed Disclaimer

Conflict of interest statement

DC and KŁ are board members in PROT sp. z o.o. and Neurare Research Foundation.

Figures

Fig. 1
Fig. 1
Comparison of the prevalence of different genetic background in the study sample and worldwide (according to Duis et al. 2022 [1])
Fig. 2
Fig. 2
Genetic tests performed during the diagnostics. Abbreviations: FISH fluorescence in situ hybridization; aCGH array comparative genomic hybridization; whole exome sequencing (WES). (Note: It was a multiple-choice question, so every participant could select multiple answers.)
Fig. 3
Fig. 3
Mean age of diagnosis depending on genetic background (deletion vs. other backgrounds). Data presented as mean ± SEM
See this image and copyright information in PMC

References

    1. Duis J, Nespeca M, Summers J, et al. A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome. Mol Genet Genom Med. 2022;10(3):1–26. 10.1002/mgg3.1843. 10.1002/mgg3.1843 - DOI - PMC - PubMed
    1. Wheeler AC, Sacco P, Cabo R. Unmet clinical needs and burden in Angelman syndrome: a review of the literature. Orphanet J Rare Dis. 2017;12(1):1–17. 10.1186/s13023-017-0716-z. 10.1186/s13023-017-0716-z - DOI - PMC - PubMed
    1. Guerrini R, Carrozzo R, Rinaldi R, Bonanni P. Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms. Pediatr Drugs. 2003;5(10):647–61. 10.2165/00148581-200305100-00001. 10.2165/00148581-200305100-00001 - DOI - PubMed
    1. Obersztyn E. Angelman syndrome. In: Śmigiel R, Szczałuba K, editors. Genetically conditioned developmental disorders in children. I. Warsaw: PZWL; 2021. p. 958–76.
    1. Śmigiel R, Łukasiewicz K, Suleja A, et al. Diagnostic and therapeutic recommendations in Angelman syndrome. Pediatr Clin. 2023;31(Neurometabolism 2023):6085–92.

Substances

LinkOut - more resources